Foundation Medicine, Inc.

Genentech, Inc.

Jie He

Doron Lipson

Jeffrey S Ross

Philip James Stephens

Matthew J Hawryluk

Vincent A Miller

Siraj Mahamed Ali

Roman Yelensky

Joel Robert Greenbowe

Geoffrey Alan Otto

David Fabrizio

David Shames

Erica Beth Schleifman

Sarah Margaret Shagan

Yan Li

Craig Anthony Cummings

Daniel Lieber

Shan Zhong

Mark Kennedy

Travis Clark

Novel fusion molecules and uses are disclosed.

Fusion molecules and uses thereof

Methods and compositions for treating cholangiocarcinoma.

Methods of treating cholangiocarcinoma

The present invention provides therapeutic, diagnostic, and prognostic methods for cancer. The invention provides methods of treating a cancer, methods of determining whether an individual having a cancer is likely to respond to a treatment including an immune checkpoint inhibitor (e.g., a PD-L1 axis binding antagonist), methods of predicting responsiveness of an individual having a cancer to a treatment including an immune checkpoint inhibitor (e.g., a PD-L1 axis binding antagonist), methods of selecting a therapy for an individual having a cancer, methods of providing a prognosis for an individual having a cancer, and methods of monitoring a response of an individual having a cancer, based on a blood tumor mutational burden (bTMB) score or a maximum somatic allele frequency (MSAF) from a sample (e.g., a whole blood sample, a plasma sample, a serum sample, or a combination thereof) from the individual.

Therapeutic and diagnostic methods for cancer

Growing community of inventors

Newton, MA, United States of America

Jie He